<DOC>
	<DOCNO>NCT00289796</DOCNO>
	<brief_summary>This study assess immunogenicity , safety reactogenicity primary booster vaccination .</brief_summary>
	<brief_title>Assess Feasibility Acellular Pertussis Vaccine ( Pa ) Given Soon After Birth , Followed 3-dose Primary Vaccination With DTPa-HBV-IPV/Hib Vaccine</brief_title>
	<detailed_description>`` There two group study : - one group receive birth dose Pa vaccine 3 dose DTPa-HBV-IPV/Hib vaccine primary vaccination dose DTPa-HBV-IPV/Hib vaccine booster vaccination - control group receive birth dose hepatitis B vaccine 3 dose DTPa-HBV-IPV/Hib vaccine primary vaccination dose DTPa-HBV-IPV/Hib vaccine booster vaccination '' .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion For primary vaccination phase Healthy newborn male female infant 2 5 day old time first vaccination &amp; write informed consent take parents/guardians subject Born term ( gestational age 3742 week ) uncomplicated pregnancy Birth weight &gt; = 2.5 kg 5 minute Apgar &gt; = 7 Mother seronegative Hepatitis B surface antigen ( HBsAg ) For booster vaccination phase A healthy male female , include , 12 23 month age time booster vaccination complete primary vaccination course primary vaccination phase write informed consent obtain parent guardian subject Exclusion criterion For primary vaccination phase Mother know suspect seropositive HIV ( test require inclusion ) Planned use investigational nonregistered product ( drug vaccine ) study vaccine study Planned administration immunosuppressant immunemodifying drug , administration immunoglobulin and/or blood product since birth plan administration study . Administration immunoglobulins and/or blood product mother pregnancy Neonatal jaundice require parenteral treatment ( light therapy physiological jaundice allow ) At risk pneumococcal disease plan receive Prevenarâ„¢ study period Administration plan administration BCG vaccination study period Acute disease time vaccination . For booster vaccination phase Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose , plan use booster phase . Evidence previous diphtheria , tetanus , pertussis , polio , hepatitis B and/or Hib booster vaccination since study conclusion visit primary vaccination phase . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Administration/ plan administration vaccine foreseen study protocol , administration/ plan administration immunoglobulins and/or blood product period start 30 day administration booster dose end 30 day booster dose . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccine dose . ''</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>